Month: June 2023

Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System. The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects. Mr. Trent Northcutt, Aurora’s President, CEO and co-founder, stated, “The launch of the study is exciting news for Aurora and its DEXA platform technology. With this multicenter study now underway, we will be able to collect and provide important data to the medical...

Vancouver, BC, June 28, 2023 (GLOBE NEWSWIRE) — Aben Minerals Ltd. (TSX-V: ABM) (OTCQB: ABNAF) (Frankfurt: R26) (“Aben” or “the Company”) is pleased to provide a Corporate update on the affairs of the Company and its Projects. The Company, going forward, is planning to advance the flagship Justin Gold Project in the Yukon that adjoins Seabridge Gold’s 3 Aces Project. The Company plans to follow up on the greenfield discovery by Aben in 2011 and 2012 at the Justin POW Zone with a highlight drill intercept of 1.25 g/t Au over 60.0m including 2.47 g/t Au over 21.0m. The Company is currently applying for a new multi year Class 3 Quartz Exploration permit to allow for advanced exploration including diamond drilling at the Justin Project. Aben also announces the resignation of Simon Dyakowski from the board of directors effective immediately....

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that long-term clinical study results from the U.S. ANAVEX®2-73-RS-001 (NCT03758924) study demonstrate disease modifying effect of ANAVEX®2-73 (blarcamesine) for adult patients with Rett syndrome. Usually, symptomatic therapies treat the symptoms of the disease but do not address the underlying cause of the disease. Disease-modifying therapies target the underlying cause of the disease. ANAVEX®2-73 (blarcamesine) is an orally available,...

 “Bullet ATM” Branded ATM Machines Will be Integrated With the Company’s Patented Technologies, Making Them the First Licensed Bitcoin ATM Network in North America RENO, NV, June 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Bullet Blockchain, Inc. (“BULT” or the “Company”), (OTC: BULT), a pioneering software development and SaaS company at the forefront of blockchain technologies and Web 3.0, is pleased to announce the successful completion of a strategic transaction to acquire a fleet of Bitcoin ATMs. As the owner and licensor of two Bitcoin ATM patents, the Company is excited to expand its offerings and provide greater accessibility to cryptocurrencies. As previously announced, BULT acquired an intellectual property portfolio consisting of Bitcoin ATM Patents (the “IP Portfolio”). BULT’s IP Portfolio will be integrated into...

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce a corporate update and preliminary financial results of Q2-2023. The update includes:Q2-2023 Revenues: Q2-2023 revenues of approximately $3.3M representing an approximately 200% increase over Q1-2023 revenues of $1.2M, this includes approximately $2.5M in sales arising from the Medical Cannabis by Shoppers platform since May 29, 2023.Medical Cannabis By Shoppers: On May 29, 2023, the Company announced that the definitive Asset Purchase Agreement with Shoppers Drug Mart Inc. for Avicanna to acquire the Medical Cannabis By Shoppers business was fully...

DETROIT, June 28, 2023 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for education, business, and government markets, announces today that V6.3 will be available to its Customers on July 10, 2023. “We are thrilled to announce the roll out of our latest update – V6.3 – utilizing a streamlined, AI-first infrastructure. Our enterprise customers are in a phase of rapid expansion, and they need reliable solutions that support their growth,” said Amesite Founder & CEO, Dr. Ann Marie Sastry. “Our AI-driven platform features can now be delivered with even greater scalability and affordability, along with greater degrees of customization, to meet our Customers’ needs.” By implementing Azure’s cloud solutions, Amesite has...

Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug development Dr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR inhibitorsJENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affairs and overseeing the launch of new drugs across multiple geographies. She will be responsible for all clinical developments related to InflaRx’s...

SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). “We are pleased to obtain the NMPA’s acceptance of our NDA for repotrectinib, which further supports repotrectinib as a potential best-in-class treatment for patients with ROS1-positive NSCLC in China. There is a significant unmet need for these patients given the limited durability of benefit, the emergence of resistance to approved therapies and eventual tumor progression,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development...

CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate. In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform. Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood. Initial data show that mice were able to generate an immune response following vaccination and antibodies...